The Dual Nature of the Antiepileptic Drug Valproic Acid, With Possible Beneficial Effects in Alzheimer’s Disease by Domagoj Đikić et al.
SEEMEDJ 2017, VOL 1, NO. 1 The Dual Nature of the Antiepileptic Drug Valproic Acid… 
 
74 Southeastern European Medical Journal, Vol 1, 2017. 
 
The Dual Nature of the Antiepileptic Drug Valproic Acid, with 
Possible Beneficial Effects in Alzheimer’s Disease 1 
Domagoj Đikić1, David Jutrić1, Kristina Dominko2 
 
1  Department of Animal Physiology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia 
2  Institute “Ruđer Bošković”, Bijenička cesta 54, Croatia 
 
Corresponding author: Domagoj Đikić, PhD - magistar_djikic1@yahoo.com 
 
Introduction 
Valproic acid (VPA) is a short, branched-chain 
fatty acid with anticonvulsant properties and one 
of the most widely prescribed drugs for many 
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types of epilepsy in children and adults. 
Typically, it is applied as the sodium salt form, 
the sodium valproate and VPA, or mixture of 
both compounds. The therapeutic concentration 
varies between 50 and 150mg/l in the serum (1-
Abstract 
Valproic acid (VPA) is a short fatty acid with strong anticonvulsant properties. It has diverse effects in different 
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antiapoptotic effects and the expression of transcription factors that promote neurite growth. Most of the 
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3). The LC-MS/MS or chemiluminescent 
microparticle immunoassay are used for 
determination of the VPA level in plasma (4). At 
serum concentrations 200mg/l and above, VPA 
can have adverse drug reactions, and it is 
necessary to lower the dosage of the drug to 
avoid the acute overdose toxic effects that may 
include hyperthermia/hypothermia, 
tachycardia, hypotension (with severe 
overdose), serious respiratory depression 
necessitating airway assistance, and cardiac 
arrest (with severe overdose). The central 
nervous system (CNS) findings in cases of VPA 
overdose may include: coma, confusion, 
somnolence, worsened seizure control, 
dizziness, hallucinations, irritability, headache, 
ataxia, and cerebral edema. Death by overdose 
and death associated with chronic 
complications in adults are recorded as well as 
death among children (1, 5). 
Although VPA is very efficient in treating 
epilepsy, its chronic therapeutic application is 
associated with many unwanted adverse drug 
reactions in certain prone patients (6).Adverse 
drug reactions, which are described within this 
manuscript from cited literature sources, 
include: weight gain, atherosclerosis, 
hypertension, nonalcoholic fatty liver disease 
(NAFLD), alterations of adipocytokine 
homeostasis, increased oxidative stress, insulin 
resistance, severe liver toxicity, death, 
abnormalities in estrogen and androgen 
metabolism, and PCOS (polycystic ovary 
syndrome) (Figure 1).  
On the other hand, experimental data, which are 
described in manuscripts from cited literature 
sources, suggest that VPA also has effects 
which seem to be beneficial regarding the 
physiology of neural tissue (Figure 2), especially 
in Alzheimer’s disease. The effects of VPA in the 
CNS seem to be completely opposite of those 
occurring in the liver and other tissues. 
By survey of the literature in Table 1, major 
search engines yield between 15000 and 17000 
hits when using the key word Valproate. In the 
last 6 years, there have been 2862 (Scopus) and 
4087 (PubMed) published papers on the subject 
of VPA (Table 1). 
This review has been written to summarize the 
latest evidence of VPA’s effects in living 
organisms. Novel physiological roles are being 
discovered, which we point to in the last chapter 
of the review. 
Metabolism, physiological and 
molecular effects 
Absorption, distribution, metabolism and 
elimination (ADME) of Valproic acid  
Pharmacokinetic and pharmacodynamic studies 
show that the absorption of short fatty acid VPA 
in the gastrointestinal system is close to 100 % 
(7,8). Because the molecular structure of VPA is 
similar to other short and long chain fatty acids, 
it follows the absorption pathways of all other 
triglycerides, cholesterol, and fatty acids.Nearly 
90% of VPA is bound to the serum proteins. Only 
the unbound portion of the compound is 
active.The biological halftime of elimination in 
patients is 6-16 hours (1).The time of elimination 
is extended in children younger than 18 months 
of age. In the organism, there are at least 50 
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known metabolites. The VPA molecule is 
partially metabolized in the cytoplasm, and 
partially in the mitochondrion where it is 
transported by the help of carnitine. Within the 
cytoplasm, it is oxidized in Phase I reactions by 
cytochrome P-450(CYP450)-catalyzed oxidation 
with the major enzymes being CYP2A6, CYP2B6 
and CYP2C9, which form major toxic metabolites 
4-eneVPA and 2-ene VPA. Cytoplasmic VPA can 
be immediately conjugated to UDP-glucuronic 
acid by UDP-glycotransferases (UGT1A3, -1A4, -
1A6, -1A7, -1A8, -1A9, -1A10 and -1A15). The 4-
ene VPA and VPA molecules enter the 
mitochondrion conjugated to CoA (4-eneVPA-
CoA and VPA-CoA) where they undergo 
mitochondrion-mediated β-oxidation and 
cytochrome P-450(CYP450)-catalyzed 
oxidation. The major metabolites of CYP450-
catalyzed oxidation are the 2-propyl-4-
pentenoic acid (4-ene-VPA), and the β-oxidation 
metabolite 2-propyl-2, 4-pentadienoic acid (2, 4-
diene-VPA). These metabolites are considered 
to be the main hepatotoxic metabolites of VPA. 
The metabolite 2-propyl-2-pentenoic acid (2-
ene-VPA), which forms through the 
mitochondrial β-oxidation, is also converted to 
the 2, 4-diene-VPA in vivo (1;7;9). In Phase II of the 
biotransformation reactions, the majority of the 
formed metabolites are subjected to further 
glucuronidation, which is considered the major 
route for VPA and metabolite elimination. To a 
lesser extent, the adverse metabolite (2,4-diene-
VPA-S-CoA) can be conjugated with glutathione 
(GSH) to form thiol conjugates, but more 
importantly it causes a decrease in 
mitochondrial glutathione levels, as described in 
rat hepatocyte cell cultures (9). The VPA 
glucuronides and their glucuronidated 
metabolites are excreted primarily by the urinary 
route and only in a small amount through the 
bile and into the intestines (1;7; 10). 
Figure 1. An overview of the physiological and adverse drug reaction effects caused by Valproic acid and Sodium Valproate 
treatment. 
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Mechanism of therapeutic action 
It is thought that the major physiologic 
mechanism of VPA’s therapeutic properties in 
epilepsy is the inhibition of 4-aminobutyrate 
aminotransferase (ABAT), a transaminase in the 
gamma aminobutyric acid (GABA) pathway. 
Therefore, VPA increases GABA release. It may 
also act by altering the properties of voltage-
dependent sodium channels. In this way, it stops 
a seizure attack during epilepsy. VPA is also a 
histone deacetylase inhibitor. With this function, 
it promotes more transcriptionally active 
chromatin structures, which is a likely epigenetic 
mechanism for the regulation of many of the 
neuroprotective effects attributed to valproic 
acid. Intermediate molecules mediating these 
effects include the Vascular endothelial growth 
factor (VEGF), the Brain-derived neurotrophic 
factor (BDNF) and the Glial cell line-derived 
neurotrophic factor (GDNF) (1, 10, 11). 
Adverse drug reactions 
Liver adverse effects 
In the liver VPA causes an accumulation of lipids, 
cholesterol, and fatty acids with the subsequent 
development of hepatic steatosis and 
nonalcoholic fatty liver disease (NAFLD) in 
patients as well as in in vitro and in vivo 
models.The hepatic adverse drug reactions 
caused by steatosis are probably due to the 
abnormalities in lipid transport, but the exact 
mechanisms of liver adverse drug reactions are 
not clear. Neither are the mechanisms by which 
VPA induces nonalcoholic fatty liver disease 
(NAFLD). Experimentally on human HepG2 cell 
lines, in vivo, VPA treatment causes leakages of 
Figure 2. An overview of the physiological effects caused by Valproic acid and Sodium valproate in neural tissue. 
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ALT, AST, and LDH in a dose dependent manner 
suggesting injury to hepatocytes (12). 
The 4-ene-VPA and 2, 4-diene-VPA metabolites 
and enzymes CYP1A1, CYP2A6, CYP2C9, ABCG1, 
and CPT1A are associated with hepatic adverse 
drug reactions in humans and in certain hepatic 
cell lines (8;12). However, only the CYP2A6 
polymorphism was found to be associated with 
higher concentrations of 4-ene-VPA and 2, 4-
diene-VPA. Potential important risk factors 
include mutated genotypes of CYP2C9 and 
CYP2A6, and higher concentrations of VPA (8). 
Exposure to sodium VPA has been shown to 
induce a down regulation of several transcripts 
in cultured hepatocytes. Their low levels 
resulted in time dependent fluctuations of 
cellular ATP, which can lead to cell death (13). 
Hepatic adverse drug reactions caused by 
VPAhave also been associated with 
mitochondrial dysfunctions, with the inhibition of 
enzymes in the beta-oxidation pathwayand with 
oxidative stress.As aforementioned, VPA can 
form thiol conjugates particularly with 
glutathione (9). Such decreases of intracellular 
glutathione levels are known to change the 
redox status of the cell and lead to the adverse 
drug reactions of oxidative stress effects. For 
example, VPA incubation of rat hepatocytes in 
vitro caused glutathione depletion which 
suggests a possible cellular oxidative stress 
after VPA exposure (9). For VPA, the role as a 
potential oxidant is underexplored, and there are 
scarce literature sources on the subject. 
Experiments on human HepG2 cell lines showed 
that exposure to VPA for more than 72h 
increased levels of mitochondrial reactive 
oxygen species production (ROS), but 
decreased protein levels of mitochondrial 
superoxide dismutase SOD2, suggesting 
oxidative stress caused by impaired elimination 
of mitochondrial ROS (13).  
Pourahmad et al. (14) and Jafarian et al. (15), both, 
in vitro, detected increases in ROS formation 
along with a decrease in mitochondrial 
membrane potential upon the treatment of rat 
liver mitochondria with VPA; all of these were 
events before cell death signaling began. 
Specifically, Jafarian et al. (15) showed that ROS 
is associated with increased lipid peroxidation, 
mitochondrial membrane collapse; 
mitochondrial swelling and finally the release of 
cytochrome c. release began apoptotic cell 
death signaling. Similarly, Pourahmadet al. (14) in 
their experiment demonstrated that the 
cytotoxic action of VPA manifests itself as 
lysosomal membrane leakiness in conjunction 
with ROS formation and a decline in membrane 
potential.Again, all were events before cell lysis 
started. 
Chang et al. (16) investigated the genetic 
polymorphisms in the G protein beta three 
subunit (GNB3) and associations with the 
metabolic phenotypes of VPA treated human 
patients.Their study confirmed that patients, 
who are T allele carriers of GNB3 C825T 
polymorphism, have a lower risk of VPA induced 
metabolic abnormalities.They warrant further 
studies investigating mechanisms of VPA 
induced metabolic abnormalities and G protein. 
An article by Stewart et al. (17) describes that the 
risk of hepatic adverse drug reactions induced 
by VPA is increased in patients with 
mitochondrial diseases, especially those with 
POLG1 gene mutations. POLG genes code for 
the mitochondrial DNA polymerase gamma and 
their mutations can cause Alpers-Huttenlocher 
syndrome, a neurometabolic disorder linked to 
an increased risk of developing fatal hepatic 
adverse drug reactions upon exposure to VPA. 
Stewart et al. (17) also described an association 
of VPA induced hepatic adverse drug reactions 
with a genetic variation in the POLG gene. In their 
case, it was a heterozygous genetic variation in 
the POLG gene which was primarily due to the 
p.Q1236H substitution, and it was strongly 
associated with VPA induced liver toxicity. In 
their experiment on primary human cell lines, 
therapeutic doses of VPA stopped human 
cellular proliferation and high doses of VPA 
induced non-apoptotic cell death, not mediated 
by mitochondrial DNA depletion, a defect infatty 
acid metabolism or mutation.Therefore, another 
mechanism of liver injury by VPA is impaired 
cellular liver regeneration.One of the ways of 
preventing it is by prospective genetic testing for 
POLG which could identify individuals at high 
SEEMEDJ 2017, VOL 1, NO. 1 The Dual Nature of the Antiepileptic Drug Valproic Acid… 
 
79 Southeastern European Medical Journal, Vol 1, 2017. 
 
risk for potentially fatal consequences of VPA 
treatment (17). 
Hepatic lipid metabolism is impaired during VPA 
treatment. The secretion of triacylglycerols and 
phospholipids at the sinusoidal pole of 
hepatocytes are reduced by an acute 
administration of VPA. This inhibition of secretion 
has been thought by Berllinger et al. (18) to be a 
factor in the development of steatogenic 
hepatic adverse drug reactions by VPA 
treatment (18) in rat hepatocytes, though so far 
shown only in an animal model. 
Gene expression profiles in hepatocytes could 
be associated with the steatogenic hepatic 
adverse drug reactions of sodium VPA. Gene 
profiling data showed striking changes in the 
expression of genes associated with lipid, fatty 
acid, steroid metabolism, oncogenesis, and 
signal transduction and development in mice 
treated with VPA (19). Lee, et al. (19), found that 
1156 genes were up and down regulated after 
exposure to sodium VPA. 60 genes were 
involved in lipid metabolism and were 
interconnected with the biological pathways for 
biosynthesis of triglycerides and cholesterol, 
catabolism of fatty acids and lipid transport (19). 
Obesity, fatty acid, and cholesterol disorders in 
patients treated with VPA 
Chronic treatment with VPA is commonly 
associated with weight gain, which potentially 
has important health implications, in particular 
increased central fat distribution. A positive 
correlation between chronic treatment with VPA 
and increased abdominal weight as well as 
increased blood pressure was recorded 
previously in human patients (20). An association 
was found between VPA induced weight gain 
and insulin resistance, hyperinsulinemia, 
hyperleptinemia and leptin resistance. 
Furthermore, the patients who had VPA induced 
weight gain were more likely to develop 
metabolic syndrome and dyslipidemia with 
associated long term vascular complications 
such as hypertension and atherosclerosis. In 
addition, they stated that long term VPA therapy 
carries a risk for atherosclerosis because of an 
accumulation of oxidative stress in combination 
with elevations of uric acid and homocysteine. 
Another experiment in human patients showed 
that VPA induced weight gain in the 
experimental group taking Valproate but noted 
weight gain was not due to decreased physical 
activity. In these participants of the study, there 
was a noted increased motivation to eat and 
decreased glucose levels in the experimental 
group compared to control group (21). 
Interestingly, quite opposite to these results in 
humans, Khan at al. (22) in their recent work in 
animal models discuss that the reason for the 
weight increase with VPA therapy might be 
increased appetite and irregular thirst, and 
consequent over-consumption of energy-rich 
alimentary. Also, they point out the dependence 
on the doses and duration of treatment, which 
changes the pharmacological signaling, 
differences in clinical and preclinical findings, as 
well as inter-species variability. The authors 
highlighted the role of histone deacetylases 
(HDACs) in insulin-resistance, gluconeogenesis 
and islet function, and formed a hypothesis that 
VPA treatment (in particular dose) might have a 
beneficial role in diabetic disorder. HDACs can 
modulate the expression of various genes, 
which directly or indirectly affect glucose 
metabolism. In their experimental work, Khan et 
al. (22), proposed and recorded the anti-diabetic 
role of VPA by the modulation of insulin 
signaling and forkhead box protein O1 (FOXO1)-
mediated gluconeogenesis in type-2 diabetic 
Sprague-Dawley rats. In the proposed model 
diabetes was induced by the combination of a 
high-fat diet and low dose streptozotocin, and 
VPA was given at the doses of 150 and 300 
mg/kg/day. VPA treatment significantly 
reduced the plasma glucose, HbA1c, insulin-
resistance, and the fat deposition in the brown 
adipose tissue, white adipose tissue and liver, 
which is comparable to metformin effects—
which the authors used as a positive control to 
create equal effects. The treatment also 
inhibited the gluconeogenesis and glucagon 
expression and recuperated the 
histopathological changes in the pancreas and 
liver. Detailed molecular mechanisms of the 
findings might elucidate the possible 
physiological mechanisms. 
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Adipokines 
As expressed in the previous chapter, in recent 
years, research focused on adipokine signaling 
to elucidate the VPA effects in increased obesity. 
It seems that without doubt, VPA affects the 
neurohormonal regulation of appetite, as 
confirmed in both patients and animal models. 
Weight gain during VPA treatment may be 
related to increases in leptin, insulin and 
neuropeptide Y (NPY) levels. Tokgoz et al.(23), 
conducted a study on 20 prepubertal children 
which compared the BMI, leptin, insulin, NPY, 
adiponectin and gherlin levels with lipid profiles, 
and CAIMT(carotid artery intima media 
thickness), before and after a treatment period 
with VPA of six to twelve months. The study 
aimed to evaluate and to determine whether 
these parameters indicate the development of 
early atherosclerosis. The treatment did not 
affect plasma ghrelin, adiponectin levels, lipid 
profiles, and CAIMT after 6 and 12 months of 
treatment compared with pretreatment values. 
Although BMI and the appetite regulatory 
molecules were changed, early atherosclerotic 
changes were not triggered within a year of 
treatment (23). A similar study on VPA therapy, 
conducted earlier on 18 children (10.94 ± 3.78 
years), showed, after 18 months of VPA 
exposure, an increase inthe serum leptin, insulin, 
and neuropeptide Y (NPY) levels, but also in the 
glucose, cortisol, galanin and ghrelin levels 
compared to the matching control. There was an 
increase of 2.3kg of body weight combined with 
an increase in named obesity signaling 
molecules in the treatment group compared to 
the control group (24).The findings of these two 
studies of decreased gherlin levels and 
increased weight gain are in stark contrast to the 
findings of the Gungor et al. (25) group which 
found increased levels of gherlin in proportion to 
an increase in weight of prepubertal patients. 
Meral et al. (26) included 44 children with 
idiopathic, generalized epilepsy treated with 
valproic acid (VPA) as an experimental group, 
and 40 children without therapy as the control 
group in their study (26). Neither the VPA treated 
group nor the control group showed any 
significant difference in terms of LDL 
cholesterol, total cholesterol and age. However, 
the VPA treated group subjects had significantly 
higher BMI-SDS as well as higher levels of 
visfatin, apelin, and triglycerides, but lower 
levels of adiponectin and HDL levels than the 
control subjects. The group concluded that 
visfatin, adiponectin and apelin can be 
considered as potential regulators of fat and 
glucose metabolism during valproic acid 
therapy (26).Grosso et al.(27) found that patients 
with VPA associated obesity had high 
concentrations of leptin in their blood. They did 
not find any differences in leptin concentration 
between patients who had VPA induced obesity 
and obese controls during their experiment. Li et 
al. (28) found that VPA can increase serum lipid 
levels in both juvenile and adult rats, but that 
higher levels of lipids could be found in juvenile 
rats (28). 
Gherlin is affected by valproic acid treatment 
and there are potential effects of such 
interactions on weight gain.A study on 35 
pediatric patients aged three to fifteen years 
were evaluated for gherlin, leptin, C-peptide, 
insulin, insulin like growth factor- 1, insulin like 
growth factor binding protein- 3 and glucose 
levels.Serum gherlin levels were increased 
significantly with a negative correlation with 
insulin like growth factor-1 and insulin like 
growth binding protein 3 in the prepubertal 
group at six months of treatment. Thus, the 
weight gain caused by valproic acid could be 
linked to the increased levels of gherlin levels in 
the early treatment period (25). 
Polycystic ovarian syndrome (PCOS) 
A higher occurrence of polycystic ovarian 
syndrome (PCOS) compared with other 
antiepileptic drugs is one of the major adverse 
drug reactions reported in women treated with 
VPA (29;30). Several molecular mechanisms 
could account for this epidemiological 
appearance. VPA treatment can be connected 
to hyperandrogenism, hyperandrogenemia, 
oligoovulaton, the appearance of PCO on 
anultra-sonogram, elevated levels of 
testosterone, and irregular menstrual cycles. 
The incidence of occurrence of PCOS in women 
taking VPA is 1.95 times higher than in women 
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being treated with other antiepileptics (31). It 
seems that VPA treatment during pregnancies 
possesses a significant risk of teratogenic 
effects based on a survey where a 15 out of 229 
(6.6%) women prescribed valproate gave birth to 
a child with a major congenital malformation 
(29). 
Since testosterone levels slightly increase, and 
progesterone and estradiol levels decrease over 
a longer treatment period with VPA, it is believed 
that such an imbalance induces polycystic 
ovarian changes and menstrual suspensions 
(amenorea) that later lead to polycystic ovarian 
syndrome (32). 
Indeed, some authors, who also recorded 
increased levels of testosterone in women 
treated with VPA for bipolar disorder, proposed 
that a broad inhibitory action on glucuronidation 
systems and on cytochrome systems causes 
high concentrations of testosterone, 
dehydroepiandrosterone sulfate, and 
androstenedione. VPA treatment over a longer 
period of time is associated with increased 
levels of testosterone. It is also associated with a 
development of menstrual abnormalities. There 
is a significant correlation between VPA 
treatment and a reduction in the levels of mRNA 
encoding estrogen receptor alpha (ER alpha), 
which causes a lack of ER alpha protein in breast 
and ovarian cell lines. Beside the regulation of 
sex physiology and menstrual abnormalities, the 
weight gain and osteoporosis could be a result 
of the lack of estrogen signaling because of the 
clearance of ER alpha protein in cell lines (33). 
Furthermore, beside the VPA interference with 
the peripheral endocrine hormones, at the 
central regulatory level of the hypothalamus-
hypophysis axis, VPA also causes decreased 
excretion of LH (luteinizing hormone), FSH 
(follicle stimulating hormone) and prolactin. 
Together, the steroid sex hormone imbalance, 
the hyperinsulinemia and obesity in humans, 
which occur due to VPA treatment, further 




Impairment of synthesis of steroid hormones 
Mechanisms of ovarian toxicity include a 
possible disruption of the pathways for the 
synthesis of sex hormones as a major cause in 
the development of PCOS. Brion et al. (35) 
expressed that VPA may increase mitochondrial 
cholesterol transport by a mechanism 
independent of the steroidogenic acute 
regulatory protein, as proven in an experimental 
model.  
Some authors explain the hormonal imbalance 
as a direct consequence of differential activity 
onthe expression of CYP enzymes involved in 
hormone synthesis, which impairs the 
conversion of testosterone to estradiol (36, 37). A 
suppression of aromatase expression takes 
place in granulosa cells as an answer to 
treatment with VPA. For example, the follicular 
development of 14-day-old rats was 
suppressed, and testosterone, estradiol, 
androstenedione, and the combined levels of all 
steroid hormones tended to decrease over time 
with exposure to VPA (38). Gustavsen et al. (37), 
found in vitro, that the expression of genes 
coding for enzymes early in steroidogenesis was 
downregulated. Such changes did not occur 
with the use of other antiepileptics (37). 
The suppression of aromatase expression 
means that the synthetic pathway from 
cholesterol to estradiol, including the de novo 
synthesis of cholesterol, is suppressed (38). 
Contrary to these in vivo results in isolated 
mitochondria, in vitro, VPA stimulates exogenous 
cholesterol conversion to progesterone (38). 
This indicates that the complex physiological 
mechanisms do not fulfill the whole picture of 
physiological interactions as in vivo. 
The majority of the mechanistic studies on 
stereidogenesis of sex hormones and ovarian 
hyperandrogenism rely on in vivo and in vitro 
investigation of VPA exposure only, and 
measurements of CYP conversion in patients is 
scarce. There are inconsistencies in the literature 
regarding the effects of VPA on the female 
reproductive steroidogenesis, as pointed out by 
Glister et al. (39) in their review of literature on 
the subject. In vivo in rodent models, Glister et al. 
(39) mention both the increase in the number of 
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follicular “cysts” and total ovarian weight with 
decreased plasma testosterone level, then list 
experiments with no effect on serum androgen 
levels. However, reduced serum estrogen levels 
affect tthe androgen/estrogen ratio, where 
androgen hormones become relatively higher. 
Interestingly, Glister (39) mentions the 
experiment on primates where VPA treatment in 
a Rhesus monkey with normal cycling had no 
effect on androgen levels or ovarian 
morphology. The authors (39) further list similar 
inconsistencies in the in vitro studies with some 
experiments: (i) recordings of increased ovarian 
androgen synthesis and an increased 
transcription of steroidogenic genes, (ii) an 
inhibitory effect of VPA on hCG-induced 
androgen secretion, (iii) increased basal and LH-
stimulated androgen secretion or decreased 
LH-stimulated androgen secretion and reduced 
basal and FSH-induced estradiol secretion. In 
their own experiment (39) in primary bovine 
theca (TC) and granulosa (GC) cells (a model 
closely relating human cycling), they exposed 
TC to VPA (7.8–500 µg/ml) with/without LH and 
GC with/without FSH or IGF analogue. In Theca 
cells, VPA reduced basal androstenedione 
secretion by 70% and in VPA/LH-induced theca 
cells by 93%. CYP17A1 mRNA was reduced by 
more than 99% and LHR, STAR, CYP11A1 and 
HSD3B1 mRNA was also lower. VPA only 
reduced theca cells progesterone secretion 
induced by the highest (luteinizing) LH dose. At 
higher concentrations (125–500 µg/ml) VPA 
inhibited basal, FSH- and IGF-stimulated 
estradiol secretion in granulose cells without 
affecting progesterone secretion. VPA reversed 
FSH-induced upregulation of CYP19A1 and 
HSD17B1 mRNA levels. Vice versa, VPA inhibits 
both LH-dependent androgen production and 
FSH/IGF-dependent estradiol production. The 
authors proposed that the named changes are 
consequences of the HDAC inhibitory properties 
and conclude that the VPA has a direct 




Alzheimer’s disease and VPA, new perspectives 
In recent work, evidence was gathered that 
besides GABA promoting effects, VPA treatment 
has antiapoptotic and protective effects in 
neural tissue (Figure2), though as with 
steroidogenesis, mostly in model experiments. 
The deinhibition of histone acetylation caused 
by histone deacetylases (HDAC s) inhibitors 
could contribute to the recovery of learning and 
memory in rats. Histone hypoacetylaton of lysine 
residues contributes to cognitive impairments in 
Alzheimer’s disease (AD).VPA can significantly 
elevate histone acetylation trough HDAC activity 
inhibition. Experiments showed that VPA 
treatment can boost the long-term recognition 
memory and spatial learning memory in AD 
transgenic mice. As such VPA could significantly 
improve cognitive function in AD (40, 41). 
Experimentally, VPA ameliorates spatial 
memory impairment and amyloid beta 
deposition in transgenic mice (42). VPA 
treatment caused a decrease in senile plaque 
formation, and Amyloid beta 40 and Amyloid 
beta 42 accumulations. Several studies, 
including those by Longet al. (43) in 2016, 
proposed that gender differences play a role in 
determining how well VPA affects the treatment 
of Alzheimer’s disease. It appears that gender 
differences play a role in the VPA effects on AD, 
since these effects were more notable in the 
male than in the female AD mice (43).  
As a histone deacetylase inhibitor, VPA is able to 
upregulate neprilysin (NEP) expression and 
activity in human neuroblastoma SH-SY5Y cell 
lines, which usually express very little NEP 
protein. Upregulation of expression and activity 
of NEP in the rat hippocampus was, also, 
observed following i.p. injections of VAP to rats. 
NEP is an amyoloid degrading enzyme which in 
the healthy brain maintains Amyloid beta levels 
at physiologically low concentrations. The 
activity and expression of these enzymes 
decreases with age and, with some other 
pathological conditions, predisposes to late 
onset of AD (40). 
The synapse damage caused by amyloid beta 
protein was reduced by pretreatment with 
physiologically relevant concentrations of VPA 
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(10 μM). VPA also decreased synaptic damage 
caused by other neurodegenerative associated 
proteins such as alpha synuclein, which is linked 
to Lewy Body dementia and Parkinson’s disease 
(44). 
VPA treatment inhibited the activity of GSK-
3beta, decreasing hyper phosphorylated Tau by 
lower phosphorylation, as seen in the transgenic 
mice (45). 
One of the main reasons of neuronal loss in AD 
is apoptosis of neurons. It seems that in neural 
tissue, VPA promotes the reduction of apoptosis 
by blocking and decreasing apoptotic signals 
and increasing survival (46). Evidence for 
reduction of apoptotic signals includes a 
significant reduction in the expression of 
interleukin 1-beta (IL-1ß) and the tumor necrosis 
factor alpha (TNF-α), as well as the micro and 
astrogliosis in the hippocampus and cortex of 
APP/PS1 transgenic mice (43). Besides the 
reduction of antiapoptotic signals, these results 
imply that VPA has anti-inflammatory properties 
in the brain that are opposite of the effects it has 
in the liver.  
Further evidence of a decrease of apoptotic 
signaling in the mouse AD model showed that 
VPA acted via the suppression of both the 
mitochondrial and the endoplasmic reticulum 
pathways of apoptosis, by downregulating the 
expression of Caspase 3, Caspase 9, Caspase 12, 
and by reducing the level of cytochrome C and 
Bax. Antiapoptotic protein BCL 2 expression was 
increased, intracellular levels of Ca2+ decreased, 
and the mitochondrial membrane potential was 
elevated (46).These are yet other effects of VPA 
which seem to be completely opposite of those 
that are occurring in the liver where apoptosis 
inducing effects were demonstrated, as 
described previously in the text. 
Most interestingly, beside the antiapoptotic 
effects, the proliferative effects in neurons, 
increase in synaptogenesis and novel 
connectivity between neurons are also 
important novel physiological roles of VPA in 
neural tissue. Experimentally, VPA caused an 
increase of CREB and BDNF expression, causing 
accelerated neurite outgrowth, modification of 
synaptic structure and improvement of 
behavioral deficits in AD mouse models. 
Accumulating evidence supporting such 
research included reports where VPA was able 
to induce MAP 2 gene expression, which 
mediated the process of de novo re-arborisation 
and neurite outgrowth of neurons. These 
functions add to the process of successful 
neuronal re-wirings (47).VPA treatment includes 
the activation of regulatory pathways that 
enhance neurogenesis and suppress 
gliogenesis. Genes which encode the 
transcription factors (TFs) that specify neuronal 
cell fate, including MEF2D, MYT1L, NEUROD1, 
PAX6 and TBR1, and their target genes, are 
induced by VPA (48). Neural stem cells (NSCs) 
derived from Niemann-Pick Type C disease 
(NPC) mice, a neurodegenerative and lipid 
storage disorder for which no effective 
treatment is known, showed impaired self-
renewal and differentiation. VPA was able to 
induce neuronal differentiation and restore 
impaired astrocytes in NSCs from NPC1 (-/-) 
mice. Increasing levels of cholesterol within NSC 
from NPC1 (-/-) mice could be reduced by VPA. 
Necessary neurotrophic genes (TrkB, BDNF, 
MnSOD, and NeruoD) were upregulated through 
the repression of the REST/NRSF and HDAC 
complex by VPA treatment. These upregulated 
neurotrophic genes were able to enhance 
neural differentiation and cholesterol 
homeostasis in neural stem cells from NPC1 (-/-
) mice (49). Such protective and beneficial role in 
AD, tau and amyloid accumulation will be the 
future of VPA research. 
Discussion and conclusion 
VPA is a short, branched chain fatty acid with 
strong anticonvulsant properties. It has diverse 
effects in different tissues, with opposing 
mechanisms of action that seem to be dose and 
exposure-time dependent (Figure 1). The 
number of papers published so far (Table 1), 
including approximately several hundred papers 
each year in the last decade, in all areas of 
physiological action, on both models and 
patients (Table 2), prove that the research on 
VPA physiology still raises interest in basic 
physiological research. The literature cited in this 
work, divided by subject area of research and 
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type of research (models and patients) (Table 2), 
is mainly from the last few years of research with 
only a few articles extended to the previous 
decade. From the comparison of cited 
physiological mechanisms, several major 
questions arise that will shape further research. 
Although a relationship between VPA 
therapeutic mechanisms and GABA action is 
generally accepted, the mechanisms of its 
adverse reactions in other tissues have not been 
fully elucidated. The major questions that will 
impact future research directions are whether 
there is a unique fundamental physiological 
mechanism that triggers different reactions in 
the tissues with opposing action, or whether the 
different tissue responses are a consequence of 
diverse target pathways induced by VPA. 
Answering this fundamental question will direct 
Table 2. Cited literature on Valproic acid and/or Valproate, divided into categories by subjects of proposed physiological 








(case, clinical and 
epidemiological 
studies) 
No. of cited papers 
(TOTAL) 
Doses and therapy   1;2;3;4;5;6;10 7 
Biotransformation 7;9;11;14 38 7;8;11;16 9 
Liver adverse 
effects 








enzymes in sex 
hormones 
biochemistry) 
35;36;37;38;39   5 
Overweight, BMI, 
adiposity 






18;49 18;19;28 16;26 7 







22 29 16;21;23;24;25 7 




neural growth  and 







No. of cited papers 
(TOTAL) 
30 17 37  
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and focus the research toward a mechanistic 
explanation of adverse effects and hypothetical 
novel properties, such as a model based 
beneficial mechanism in Alzheimer’s disease. 
The beneficial effects in neural tissue is mainly 
gained hypothetically in the models (Table 2) 
and has yet to be proven in human subjects. The 
models based on a novel proposed beneficial 
mechanism in neurons and especially in the 
protective role in the forming of Alzheimer’s 
disease should also investigate the potential of 
VPA to prevent the transmigration of 
accumulated Tau and Amyloid in already 
formed plaques within the neural tissue. 
Research of such therapeutic potential in 
patients with early signs of plaque formation 
would be more important than VPA preventive 
potential, since it is highly unlikely that the 
healthy patients could be subjected to 
therapeutic exposure to VPA as a measure of 
prevention, even if the beneficial effects in 
prevention of the first steps of accumulation, 
and hyperphosphorilation of these molecules 
are proven in humans. 
The problem of weight gain and energy 
physiology caused by the treatment with VPA 
still remains unsolved and limits all beneficiary 
actions described in neural tissues. Although 
noted in patients and animal models, the 
adverse drug effects on adiposity and lipid 
accumulation has not been clearly explained. It 
is believed that the hepatocyte mitochondrion 
disturbance is a major cause of imbalance of 
lipid metabolism in the liver and one of the 
causes of weight gain observed in patients 
treated with VPA. However, even though some 
genetic predispositions (such as POLG mutation) 
have been detected, it seems from the cited 
references that the effects could be more 
epigenetic in nature, and future research should 
focus on designing experiments connecting 
targeted genetic predisposition (mutations) and 
epigenetics. Furthermore, the hepatocyte lipid 
imbalance should be further investigated 
physiologically from the point of major 
conversing enzymes along the biochemical 
pathways of triglyceride, fatty acid and 
cholesterol synthesis/biochemical 
redistribution and lipoprotein synthesis and 
redistribution (for example Acetyl-CoA 
carboxylases 1 and 2 (ACC1 and ACC2), fatty acid 
synthetase (FAS), Stearoyl-CoA desaturase-1 or 
carnitine/palmitoyl-transferase 1 etc.). 
References in this direction of research are 
missing. Besides the proposed hepatic adverse 
drug reactions that influence lipid metabolism 
and transport, recently, the research 
concentrated on the role of appetite regulation 
pathways involving adipokines and other 
metabolic regulating hormones. This subject is 
abundant in the literature with both evidence 
from the patients and animal models. The exact 
question that future experimental design has to 
focus on would be whether adipokine 
disturbance (increase) is directly unleashed by 
VPA action as a cause or whether it is a 
consequence of adipocyte (and GI) reaction to 
differential fatty acids. There is a probability that 
adipokine activation and appetite 
enhancements are merely a consequence of 
disturbed lipid physiology within the adipocytes 
or hepatocytes. Besides lipid physiology, due to 
the abnormal effects on energy, fatty acid, and 
cholesterol metabolism, VPA treatment is a risk 
factor for the development of other metabolic 
diseases with its associated complications such 
as atherosclerosis, and metabolic syndrome, 
while in the CNS it has many beneficial effects. 
Research should also focus on the physiological 
pathways of cholesterol transport and 
metabolism not only in experimental models 
(Table 2), but in the liver, reproductive organs 
(stereidogenesis) and in neural cells of patients 
as well.  
It seems that in the last decade the research 
field of oxidative stress has been abandoned or 
reduced in vivo (Table 2). In addition to the 
biochemical pathways of lipid metabolism, the 
cellular redox status of biochemical balance 
might also be important in contributing to the 
differential activation of physiological pathways 
of lipid metabolism and epigenetic changes that 
may enhance pathophysiological changes. 
Thus, future studies on VPA physiology should 
neither neglect this area of research. Within all 
prospect studies, special attention should be 
given to the doses of exposure. 
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In conclusion, although prescribed as an 
effective anticonvulsant, most of the pathogenic 
pathways of VPA’s unwanted and beneficial 
molecular effects are not fully understood and 
further studies and experiments are warranted. 
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